Makaleler
12
Tümü (12)
SCI-E, SSCI, AHCI (11)
SCI-E, SSCI, AHCI, ESCI (12)
ESCI (1)
Scopus (12)
12. Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
, cilt.33, sa.1, ss.1352-1361, 2018 (SCI-Expanded)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
10
1. EVALUATION OF NOVEL THIAZOLE-5-CARBOXAMIDE-IMIDAZOLIDINONE DERIVATIVES AS POTENT HUMAN SOLUBLE EPOXIDE HYDROLASE INHIBITORS
59th International Conference on Medicinal Chemistry (RICT 2025), Orleans, Fransa, 02 Temmuz 2025, (Özet Bildiri)
2. Novel Benzimidazole Amide Derivatives as Human Soluble Epoxide Hydrolase (sEH) Inhibitors
58TH INTERNATIONAL CONFERENCE ON MEDICINAL CHEMISTRY, Bordeaux, Fransa, 3 - 05 Temmuz 2024, ss.188, (Özet Bildiri)
3. PYRIDAZINYL-PHENYL BENZYL UREA DERIVATIVES AS HUMAN SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS
Medicinal Chemistry Frontiers 2024, Utrecht, Hollanda, 08 Nisan 2024, (Özet Bildiri)
4. SYNTHESIS, BIOLOGICAL EVALUATION AND MOLECULAR DOCKING STUDIES OF NEW 1-(2-CHLOROPHENYL)UREA DERIVATIVES AS INHIBITORS OF HUMAN SOLUBLE EPOXIDE HYDROLASE
International Multidisciplinary Symposium on Drug Research and Development (DRD) 2023, İzmir, Türkiye, 4 - 06 Mayıs 2023, ss.204, (Özet Bildiri)
6. KARACİĞER KANSERİ KÖK HÜCRELERİ ÜZERİNDE İNHİBİTÖR ETKİYE SAHİP, POTANSİYEL ANTİKANSER AJANLAR OLARAK YENİ İZOKSAZOL-PİPERAZİN HİBRİTLERİNİN SENTEZİ VE BİYOLOJİK OLARAK DEĞERLENDİRİLMESİ
VI. Ulusal Farmasötik Kimya Kongresi, İstanbul, Türkiye, 26 - 29 Ağustos 2022, (Özet Bildiri)
8. SYNTHESIS AND ANTIPROLIFERATIVE EVALUATION OF NOVEL ISOXAZOLE-PIPERAZINE HYBRIDS
RICT 2018, 4 - 06 Temmuz 2018, (Özet Bildiri)
9. SYNTHESIS, CYTOTOXICITY AND STRUCTURE-ACTIVITYRELATIONSHIPS OF NOVEL ISOXAZOLE DERIVATIVES ASANTICANCER AGENTS
RICT 2018, 4 - 06 Temmuz 2018, (Özet Bildiri)
10. Discovery and Development of Novel Anti-cancer and Anti-inflammatory Compounds: Medicinal Chemistry Challenges
The 4th International Symposium on Pharmaceutical and Biomedical Sciences, Kumamoto, Japonya, 17 Mart 2018, (Özet Bildiri)